The U.S. Food and Drug Administration said on Monday that it had launched a generative AI tool, Elsa, aimed at improving efficiency across its operations, including scientific reviews.
“Today’s rollout of Elsa is ahead of schedule and under budget, thanks to the collaboration of our in-house experts across the centers,” said FDA Commissioner Marty Makary.
The agency said it is already using Elsa to expedite clinical protocol reviews, shorten the time needed for scientific evaluations, and pinpoint high-priority inspection targets.
Once the FDA receives an application for a potential drug approval, it has six to 10 months to make a decision.
Elsa assists with reading, writing, and summarizing tasks. It can summarize adverse events to support safety profile assessments of drugs and rapidly compare packaging inserts.
“Elsa offers a secure platform for FDA employees to access internal documents while ensuring all information remains within the agency. The models do not train on data submitted by regulated industry, safeguarding the sensitive research and data handled by FDA staff,” the FDA said.
In May, the regulator said it would fully integrate AI by June 30, following an experimental run.
—Puyaan Singh, Reuters
Melden Sie sich an, um einen Kommentar hinzuzufügen
Andere Beiträge in dieser Gruppe
The Trump administration has announced sweeping tariffs—ranging from 10% to 41
If you’ve ever experienced incommensurate rage from slow or oblivious walkers, this Ti
The Apple TV is probably my favorite device that Apple makes. While the Apple TV app is in dire need
Sometimes, the simplest photo feats are the most satisfying of all.
Me? I’ve lost count of the number of times I’ve needed to remove the background from an image for one reason or anothe
A federal appeals court has upheld a jury verdict condemning Google’s Android app store as an illegal monopoly, clearing the way for a federal judge to enforce a potentially disruptive shake
Apple shares rose 2% in premarket trading on Friday, after the
OpenAI has removed a controversial opt-in feature that had led to some private chats appearing in Google search results, following reporting by Fast Company that found sensitive conversa
